FAM219B

Across TCGA pan-cancer cohorts, FAM219B RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of FAM219B’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where FAM219B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FAM219B is over-expressed in tumor, although a few such as LUAD and KICH show the opposite, repressed pattern.

LIHC, LUAD, and KICH are the cancer types where FAM219B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FAM219B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.934	<.001	9	view →
LUAD	Female	III,IV	−0.711	<.001	7	view →
KICH	Male	All	−0.641	<.001	7	view →
BRCA	All	All	−0.640	<.001	6	view →
CHOL	All	All	+1.897	<.001	5	view →
LUSC	All	III,IV	−0.573	.019	3	view →
STAD	Female	All	−0.751	.047	2	view →
UCEC	All	All	−0.590	.004	2	view →
READ	All	All	−0.402	.043	1	view →
KIRC	Female	All	+0.357	.028	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

FAM219B–LIHC

Open the LIHC breakdown →